Texas-based gene therapy company Genprex Inc., (NASDAQ: GNPX), has reported receiving a patent protection award in China for its lead pipeline candidate, Reqorsa (ONC-001/2) immunogene therapy. The China Intellectual Property Administration (CNIPA) has granted patent No: 201780076886.X, which covers the use of the therapy in combination with PD-1 antibodies, providing protection up until 2037.
Expanding Global Patent Coverage for Reqorsa
Genprex’s receipt of this patent award in China adds to the existing patent coverage for its Phase II stage product in the United States, Mexico, Japan, Australia, and Russia. This expansion of intellectual property rights further solidifies Genprex’s position in the global market and strengthens the protection of its innovative gene therapy.
Non-Viral Gene Therapy Platform and Clinical Trials
Genprex is utilizing a non-viral gene therapy platform to develop treatments for cancer and diabetes. Reqorsa is currently undergoing two Phase I/II trials, assessing its efficacy in non-small cell lung cancer (NSCLC) in combination with Tagrisso (osimertinib) and Keytruda (pembrolizumab), respectively. These trials are crucial for evaluating the potential benefits of Reqorsa in combination with existing immunotherapies, which could significantly impact the treatment landscape for patients with NSCLC.-Fineline Info & Tech
